{"id":617,"date":"2026-03-24T07:40:11","date_gmt":"2026-03-24T14:40:11","guid":{"rendered":"https:\/\/www.leapfrog.bio\/?p=617"},"modified":"2026-03-24T07:56:32","modified_gmt":"2026-03-24T14:56:32","slug":"leapfrog-bio-appoints-alan-ashworth-ph-d-frs-to-chair-companys-scientific-advisory-board","status":"publish","type":"post","link":"https:\/\/www.leapfrog.bio\/fr\/leapfrog-bio-appoints-alan-ashworth-ph-d-frs-to-chair-companys-scientific-advisory-board\/","title":{"rendered":"Leapfrog Bio nomme Alan Ashworth, Ph.D., FRS, comme pr\u00e9sident de son conseil consultatif scientifique"},"content":{"rendered":"<div class=\"fusion-fullwidth fullwidth-box fusion-builder-row-1 fusion-flex-container nonhundred-percent-fullwidth non-hundred-percent-height-scrolling\" style=\"--awb-border-radius-top-left:0px;--awb-border-radius-top-right:0px;--awb-border-radius-bottom-right:0px;--awb-border-radius-bottom-left:0px;--awb-flex-wrap:wrap;\" ><div class=\"fusion-builder-row fusion-row fusion-flex-align-items-flex-start fusion-flex-content-wrap\" style=\"max-width:1352px;margin-left: calc(-4% \/ 2 );margin-right: calc(-4% \/ 2 );\"><div class=\"fusion-layout-column fusion_builder_column fusion-builder-column-0 fusion_builder_column_1_1 1_1 fusion-flex-column\" style=\"--awb-bg-blend:overlay;--awb-bg-size:cover;--awb-width-large:100%;--awb-margin-top-large:0px;--awb-spacing-right-large:1.92%;--awb-margin-bottom-large:0px;--awb-spacing-left-large:1.92%;--awb-width-medium:100%;--awb-spacing-right-medium:1.92%;--awb-spacing-left-medium:1.92%;--awb-width-small:100%;--awb-spacing-right-small:1.92%;--awb-spacing-left-small:1.92%;\"><div class=\"fusion-column-wrapper fusion-flex-justify-content-flex-start fusion-content-layout-column\"><div class=\"fusion-text fusion-text-1\"><p align=\"center\">\u2014Le Dr Ashworth apporte des d\u00e9cennies d'exp\u00e9rience scientifique et clinique pour traduire les d\u00e9couvertes sur la l\u00e9talit\u00e9 synth\u00e9tique en<br \/>th\u00e9rapies anticanc\u00e9reuses de pr\u00e9cision \u2014<\/p>\n<p style=\"text-align: center;\">\n<p>South San Francisco (Californie), le 24 mars 2026<b> <\/b><span style=\"letter-spacing: 0.27px; background-color: rgba(0, 0, 0, 0);\">(<span style=\"color: rgb(133, 175, 189);\"><span style=\"color: rgb(133, 175, 189);\"><u><a href=\"https:\/\/www.globenewswire.com\/news-release\/2026\/03\/24\/3261170\/0\/en\/Leapfrog-Bio-Appoints-Alan-Ashworth-Ph-D-FRS-to-Chair-Company-s-Scientific-Advisory-Board.html\" target=\"_blank\" rel=\"noopener noreferrer\" style=\"color: rgb(133, 175, 189);\">Lire sur GlobeNewswire<\/a><\/u><\/span><\/span>)<\/span><b style=\"letter-spacing: 0.27px; background-color: rgba(0, 0, 0, 0);\"> \u2014<\/b><span style=\"letter-spacing: 0.27px; background-color: rgba(0, 0, 0, 0);\"> <\/span>Leapfrog Bio, une soci\u00e9t\u00e9 d\u2019oncologie de pr\u00e9cision au stade clinique d\u00e9di\u00e9e \u00e0 la d\u00e9couverte et au d\u00e9veloppement de nouvelles th\u00e9rapies cibl\u00e9es pour les cancers associ\u00e9s \u00e0 des mutations avec perte de fonction (LOF), a annonc\u00e9 aujourd\u2019hui la nomination d\u2019Alan Ashworth, Ph. D., FRS, \u00e0 la pr\u00e9sidence de son conseil consultatif scientifique.<\/p>\n<p>Le Dr Ashworth est un expert de renomm\u00e9e mondiale en recherche sur le cancer et un chef de file international dans le d\u00e9veloppement de th\u00e9rapies oncologiques. Il a jou\u00e9 un r\u00f4le d\u00e9terminant dans l\u2019identification du g\u00e8ne BRCA2 et a contribu\u00e9 \u00e0 \u00e9tablir son r\u00f4le dans la r\u00e9paration de l\u2019ADN et la recombinaison homologue \u2014 des travaux qui ont ouvert la voie \u00e0 l\u2019inhibition de PARP comme strat\u00e9gie th\u00e9rapeutique.\n\nLa d\u00e9couverte, par son \u00e9quipe, de la relation de l\u00e9talit\u00e9 synth\u00e9tique entre BRCA1\/2 et les inhibiteurs de PARP a orient\u00e9 le d\u00e9veloppement de l\u2019olaparib, premier inhibiteur de PARP cibl\u00e9 sur le plan g\u00e9n\u00e9tique \u00e0 avoir \u00e9t\u00e9 approuv\u00e9, constituant une validation clinique majeure de l\u2019approche de l\u00e9talit\u00e9 synth\u00e9tique. Au fil des d\u00e9cennies, le Dr Ashworth a contribu\u00e9 \u00e0 de nombreux programmes visant \u00e0 traduire les relations de l\u00e9talit\u00e9 synth\u00e9tique en th\u00e9rapies anticanc\u00e9reuses transformatrices.<\/p>\n<p>\u00ab Nous sommes ravis d\u2019accueillir le Dr Ashworth au sein de notre conseil consultatif scientifique \u00bb, a d\u00e9clar\u00e9 Tomas Babak, Ph. D., fondateur et directeur scientifique de Leapfrog Bio. \u00ab Peu de scientifiques ont autant contribu\u00e9 \u00e0 l\u2019application clinique de la l\u00e9talit\u00e9 synth\u00e9tique ou d\u00e9montr\u00e9 une compr\u00e9hension aussi approfondie de la fa\u00e7on de transformer des d\u00e9couvertes biologiques en b\u00e9n\u00e9fices concrets pour les patients.\n\nDe la d\u00e9couverte de la l\u00e9talit\u00e9 synth\u00e9tique entre BRCA et PARP, qui a permis le succ\u00e8s des inhibiteurs de PARP, \u00e0 la direction de grands centres de recherche en oncologie et \u00e0 la cr\u00e9ation d\u2019entreprises biopharmaceutiques, Alan poss\u00e8de une exp\u00e9rience exceptionnelle qui contribuera \u00e0 orienter nos propres programmes de d\u00e9veloppement.\n\nComme l\u2019ont d\u00e9montr\u00e9 les inhibiteurs de PARP, l\u2019\u00e9valuation des effets pharmacologiques des m\u00e9dicaments en synergie avec des perturbations g\u00e9n\u00e9tiques est essentielle pour exploiter pleinement leur potentiel en tant qu\u2019agents cibl\u00e9s sur le plan g\u00e9n\u00e9tique. La perspective d\u2019Alan renforce notre conviction que notre approche pharmacog\u00e9n\u00e9tique ouvrira la voie \u00e0 des opportunit\u00e9s prometteuses dans le domaine de la l\u00e9talit\u00e9 synth\u00e9tique. \u00bb<\/p>\n<p>Leapfrog applique une approche pharmacog\u00e9n\u00e9tique syst\u00e9matique pour mettre en \u00e9vidence des vuln\u00e9rabilit\u00e9s g\u00e9n\u00e9tiquement d\u00e9finies dans le cancer, en \u00e9tendant le paradigme de la l\u00e9talit\u00e9 synth\u00e9tique \u00e0 de nouveaux cancers \u00e0 fort impact associ\u00e9s \u00e0 des mutations avec perte de fonction.\n\nLe portefeuille de la soci\u00e9t\u00e9 comprend LFB190, un inhibiteur de BET destin\u00e9 au traitement de tumeurs solides associ\u00e9es \u00e0 des mutations avec perte de fonction du g\u00e8ne EP300, ainsi que LFB083, qui cible des cancers associ\u00e9s \u00e0 des mutations du g\u00e8ne PIK3CA. Les deux programmes ont \u00e9t\u00e9 identifi\u00e9s gr\u00e2ce \u00e0 la plateforme exclusive OncoSLX de Leapfrog.<\/p>\n<p>\u00ab Nos travaux sur la l\u00e9talit\u00e9 synth\u00e9tique entre les mutations BRCA et les inhibiteurs de PARP ont transform\u00e9 notre fa\u00e7on d\u2019aborder le traitement des cancers associ\u00e9s \u00e0 des mutations avec perte de fonction \u00bb, a d\u00e9clar\u00e9 Alan Ashworth, Ph. D., FRS. \u00ab Ce qui me motive particuli\u00e8rement chez Leapfrog Bio, c\u2019est le parall\u00e8le clair entre nos premiers travaux sur les inhibiteurs de PARP et les d\u00e9couvertes de l\u2019entreprise concernant l\u2019inhibition de BET dans les cancers associ\u00e9s \u00e0 des mutations avec perte de fonction du g\u00e8ne EP300, ainsi que l\u2019ensemble de ses travaux en l\u00e9talit\u00e9 synth\u00e9tique.\n\nAvec deux programmes particuli\u00e8rement prometteurs et une plateforme capable d\u2019en g\u00e9n\u00e9rer de nombreux autres, il s\u2019agit d\u2019une occasion exceptionnelle, et je suis ravi de me joindre au conseil consultatif scientifique. \u00bb<\/p>\n<p>Le Dr Ashworth est actuellement pr\u00e9sident du Helen Diller Family Comprehensive Cancer Center \u00e0 l\u2019University of California, San Francisco, ainsi que vice-pr\u00e9sident principal, services cliniques en oncologie, chez UCSF Health. Il si\u00e8ge au conseil d\u2019administration de CytomX Therapeutics et est cofondateur de Tango Therapeutics, Azkarra Therapeutics et Tiller Therapeutics.\n\nAuparavant, il a \u00e9t\u00e9 chef de la direction de l\u2019Institute of Cancer Research \u00e0 Londres et directeur du Breakthrough Breast Cancer Research Centre. Il est membre \u00e9lu de l\u2019European Molecular Biology Organization, de l\u2019Academy of Medical Sciences, et Fellow de la Royal Society.\n\nLe Dr Ashworth est titulaire d\u2019un doctorat en biochimie de University College London et d\u2019un baccalaur\u00e9at en chimie et biochimie de l\u2019Imperial College London.<\/p>\n<p><b>\u00c0 propos de Leapfrog Bio<br \/><\/b>Leapfrog Bio est une soci\u00e9t\u00e9 d\u2019oncologie de pr\u00e9cision au stade clinique qui acc\u00e9l\u00e8re le d\u00e9veloppement de m\u00e9dicaments contre le cancer en identifiant des mol\u00e9cules d\u00e9j\u00e0 en phase clinique pouvant \u00eatre repositionn\u00e9es comme th\u00e9rapies de pr\u00e9cision pour des cancers associ\u00e9s \u00e0 des mutations avec perte de fonction (LOF).\n\nSon principal programme, LFB190, est un inhibiteur de BET oral, premier de sa cat\u00e9gorie, pr\u00eat pour la phase 2, destin\u00e9 au traitement de tumeurs solides associ\u00e9es \u00e0 des mutations avec perte de fonction du g\u00e8ne EP300.\n\nLeapfrog Bio s\u2019appuie sur sa plateforme exclusive OncoSLX pour identifier des m\u00e9dicaments \u00e0 petites mol\u00e9cules existants pouvant \u00eatre d\u00e9velopp\u00e9s afin de traiter des cancers li\u00e9s \u00e0 des mutations avec perte de fonction, avec une forte probabilit\u00e9 de succ\u00e8s clinique.\n\nLeapfrog Bio est actuellement financ\u00e9e au stade d\u2019amor\u00e7age par le fonds d\u2019investissement en biotechnologie Two Bear Capital. Pour en savoir plus, visitez <a href=\"https:\/\/www.leapfrog.bio\/fr\/\" style=\"color: rgb(133, 175, 189);\"><u><span style=\"color: rgb(133, 175, 189);\">www.leapfrog.bio<\/span><\/u><\/a>.<\/p>\n<p><b>Relations avec les investisseurs<\/b>:<br \/>Max Gadicke<br \/>Precision AQ<br \/><span style=\"color: rgb(133, 175, 189);\"><a href=\"\/fr\/maximilian.gadicke@precisionaq.com\/\" style=\"color: rgb(133, 175, 189);\"><u>maximilian.gadicke@precisionaq.com<\/u><\/a><\/span><\/p>\n<\/div><\/div><\/div><\/div><\/div>","protected":false},"excerpt":{"rendered":"","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_links_to":"","_links_to_target":""},"categories":[1],"tags":[],"class_list":["post-617","post","type-post","status-publish","format-standard","hentry","category-uncategorized"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v24.1 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Leapfrog Bio Appoints Alan Ashworth, Ph.D., FRS, to Chair Company\u2019s Scientific Advisory Board - Leapfrog Bio<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.leapfrog.bio\/fr\/leapfrog-bio-appoints-alan-ashworth-ph-d-frs-to-chair-companys-scientific-advisory-board\/\" \/>\n<meta property=\"og:locale\" content=\"fr_CA\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Leapfrog Bio Appoints Alan Ashworth, Ph.D., FRS, to Chair Company\u2019s Scientific Advisory Board - Leapfrog Bio\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.leapfrog.bio\/fr\/leapfrog-bio-appoints-alan-ashworth-ph-d-frs-to-chair-companys-scientific-advisory-board\/\" \/>\n<meta property=\"og:site_name\" content=\"Leapfrog Bio\" \/>\n<meta property=\"article:published_time\" content=\"2026-03-24T14:40:11+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-03-24T14:56:32+00:00\" \/>\n<meta name=\"author\" content=\"leapfrogbio\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"leapfrogbio\" \/>\n\t<meta name=\"twitter:label2\" content=\"Estimation du temps de lecture\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/www.leapfrog.bio\/leapfrog-bio-appoints-alan-ashworth-ph-d-frs-to-chair-companys-scientific-advisory-board\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/www.leapfrog.bio\/leapfrog-bio-appoints-alan-ashworth-ph-d-frs-to-chair-companys-scientific-advisory-board\/\"},\"author\":{\"name\":\"leapfrogbio\",\"@id\":\"https:\/\/www.leapfrog.bio\/#\/schema\/person\/92a5cc02e124e50a860cfb11866fc6a3\"},\"headline\":\"Leapfrog Bio Appoints Alan Ashworth, Ph.D., FRS, to Chair Company\u2019s Scientific Advisory Board\",\"datePublished\":\"2026-03-24T14:40:11+00:00\",\"dateModified\":\"2026-03-24T14:56:32+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/www.leapfrog.bio\/leapfrog-bio-appoints-alan-ashworth-ph-d-frs-to-chair-companys-scientific-advisory-board\/\"},\"wordCount\":868,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/www.leapfrog.bio\/#organization\"},\"articleSection\":[\"Uncategorized\"],\"inLanguage\":\"fr-CA\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/www.leapfrog.bio\/leapfrog-bio-appoints-alan-ashworth-ph-d-frs-to-chair-companys-scientific-advisory-board\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.leapfrog.bio\/leapfrog-bio-appoints-alan-ashworth-ph-d-frs-to-chair-companys-scientific-advisory-board\/\",\"url\":\"https:\/\/www.leapfrog.bio\/leapfrog-bio-appoints-alan-ashworth-ph-d-frs-to-chair-companys-scientific-advisory-board\/\",\"name\":\"Leapfrog Bio Appoints Alan Ashworth, Ph.D., FRS, to Chair Company\u2019s Scientific Advisory Board - Leapfrog Bio\",\"isPartOf\":{\"@id\":\"https:\/\/www.leapfrog.bio\/#website\"},\"datePublished\":\"2026-03-24T14:40:11+00:00\",\"dateModified\":\"2026-03-24T14:56:32+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/www.leapfrog.bio\/leapfrog-bio-appoints-alan-ashworth-ph-d-frs-to-chair-companys-scientific-advisory-board\/#breadcrumb\"},\"inLanguage\":\"fr-CA\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.leapfrog.bio\/leapfrog-bio-appoints-alan-ashworth-ph-d-frs-to-chair-companys-scientific-advisory-board\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.leapfrog.bio\/leapfrog-bio-appoints-alan-ashworth-ph-d-frs-to-chair-companys-scientific-advisory-board\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.leapfrog.bio\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Leapfrog Bio Appoints Alan Ashworth, Ph.D., FRS, to Chair Company\u2019s Scientific Advisory Board\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.leapfrog.bio\/#website\",\"url\":\"https:\/\/www.leapfrog.bio\/\",\"name\":\"Leapfrog Bio\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/www.leapfrog.bio\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.leapfrog.bio\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-CA\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.leapfrog.bio\/#organization\",\"name\":\"Leapfrog Bio\",\"url\":\"https:\/\/www.leapfrog.bio\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-CA\",\"@id\":\"https:\/\/www.leapfrog.bio\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.leapfrog.bio\/wp-content\/uploads\/2022\/09\/leapfrogbio-logo-retina1.png\",\"contentUrl\":\"https:\/\/www.leapfrog.bio\/wp-content\/uploads\/2022\/09\/leapfrogbio-logo-retina1.png\",\"width\":510,\"height\":90,\"caption\":\"Leapfrog Bio\"},\"image\":{\"@id\":\"https:\/\/www.leapfrog.bio\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.leapfrog.bio\/#\/schema\/person\/92a5cc02e124e50a860cfb11866fc6a3\",\"name\":\"leapfrogbio\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-CA\",\"@id\":\"https:\/\/www.leapfrog.bio\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/08f1d19ee324ad5cbca6f1c4e0ea138b6167a555400e405437d73b83bb0af4e9?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/08f1d19ee324ad5cbca6f1c4e0ea138b6167a555400e405437d73b83bb0af4e9?s=96&d=mm&r=g\",\"caption\":\"leapfrogbio\"},\"sameAs\":[\"https:\/\/www.leapfrog.bio\"],\"url\":\"https:\/\/www.leapfrog.bio\/fr\/author\/leapfrogbio\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Leapfrog Bio Appoints Alan Ashworth, Ph.D., FRS, to Chair Company\u2019s Scientific Advisory Board - Leapfrog Bio","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.leapfrog.bio\/fr\/leapfrog-bio-appoints-alan-ashworth-ph-d-frs-to-chair-companys-scientific-advisory-board\/","og_locale":"fr_CA","og_type":"article","og_title":"Leapfrog Bio Appoints Alan Ashworth, Ph.D., FRS, to Chair Company\u2019s Scientific Advisory Board - Leapfrog Bio","og_url":"https:\/\/www.leapfrog.bio\/fr\/leapfrog-bio-appoints-alan-ashworth-ph-d-frs-to-chair-companys-scientific-advisory-board\/","og_site_name":"Leapfrog Bio","article_published_time":"2026-03-24T14:40:11+00:00","article_modified_time":"2026-03-24T14:56:32+00:00","author":"leapfrogbio","twitter_card":"summary_large_image","twitter_misc":{"\u00c9crit par":"leapfrogbio","Estimation du temps de lecture":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.leapfrog.bio\/leapfrog-bio-appoints-alan-ashworth-ph-d-frs-to-chair-companys-scientific-advisory-board\/#article","isPartOf":{"@id":"https:\/\/www.leapfrog.bio\/leapfrog-bio-appoints-alan-ashworth-ph-d-frs-to-chair-companys-scientific-advisory-board\/"},"author":{"name":"leapfrogbio","@id":"https:\/\/www.leapfrog.bio\/#\/schema\/person\/92a5cc02e124e50a860cfb11866fc6a3"},"headline":"Leapfrog Bio Appoints Alan Ashworth, Ph.D., FRS, to Chair Company\u2019s Scientific Advisory Board","datePublished":"2026-03-24T14:40:11+00:00","dateModified":"2026-03-24T14:56:32+00:00","mainEntityOfPage":{"@id":"https:\/\/www.leapfrog.bio\/leapfrog-bio-appoints-alan-ashworth-ph-d-frs-to-chair-companys-scientific-advisory-board\/"},"wordCount":868,"commentCount":0,"publisher":{"@id":"https:\/\/www.leapfrog.bio\/#organization"},"articleSection":["Uncategorized"],"inLanguage":"fr-CA","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/www.leapfrog.bio\/leapfrog-bio-appoints-alan-ashworth-ph-d-frs-to-chair-companys-scientific-advisory-board\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/www.leapfrog.bio\/leapfrog-bio-appoints-alan-ashworth-ph-d-frs-to-chair-companys-scientific-advisory-board\/","url":"https:\/\/www.leapfrog.bio\/leapfrog-bio-appoints-alan-ashworth-ph-d-frs-to-chair-companys-scientific-advisory-board\/","name":"Leapfrog Bio Appoints Alan Ashworth, Ph.D., FRS, to Chair Company\u2019s Scientific Advisory Board - Leapfrog Bio","isPartOf":{"@id":"https:\/\/www.leapfrog.bio\/#website"},"datePublished":"2026-03-24T14:40:11+00:00","dateModified":"2026-03-24T14:56:32+00:00","breadcrumb":{"@id":"https:\/\/www.leapfrog.bio\/leapfrog-bio-appoints-alan-ashworth-ph-d-frs-to-chair-companys-scientific-advisory-board\/#breadcrumb"},"inLanguage":"fr-CA","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.leapfrog.bio\/leapfrog-bio-appoints-alan-ashworth-ph-d-frs-to-chair-companys-scientific-advisory-board\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.leapfrog.bio\/leapfrog-bio-appoints-alan-ashworth-ph-d-frs-to-chair-companys-scientific-advisory-board\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.leapfrog.bio\/"},{"@type":"ListItem","position":2,"name":"Leapfrog Bio Appoints Alan Ashworth, Ph.D., FRS, to Chair Company\u2019s Scientific Advisory Board"}]},{"@type":"WebSite","@id":"https:\/\/www.leapfrog.bio\/#website","url":"https:\/\/www.leapfrog.bio\/","name":"Leapfrog Bio","description":"","publisher":{"@id":"https:\/\/www.leapfrog.bio\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.leapfrog.bio\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-CA"},{"@type":"Organization","@id":"https:\/\/www.leapfrog.bio\/#organization","name":"Leapfrog Bio","url":"https:\/\/www.leapfrog.bio\/","logo":{"@type":"ImageObject","inLanguage":"fr-CA","@id":"https:\/\/www.leapfrog.bio\/#\/schema\/logo\/image\/","url":"https:\/\/www.leapfrog.bio\/wp-content\/uploads\/2022\/09\/leapfrogbio-logo-retina1.png","contentUrl":"https:\/\/www.leapfrog.bio\/wp-content\/uploads\/2022\/09\/leapfrogbio-logo-retina1.png","width":510,"height":90,"caption":"Leapfrog Bio"},"image":{"@id":"https:\/\/www.leapfrog.bio\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/www.leapfrog.bio\/#\/schema\/person\/92a5cc02e124e50a860cfb11866fc6a3","name":"leapfrogbio","image":{"@type":"ImageObject","inLanguage":"fr-CA","@id":"https:\/\/www.leapfrog.bio\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/08f1d19ee324ad5cbca6f1c4e0ea138b6167a555400e405437d73b83bb0af4e9?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/08f1d19ee324ad5cbca6f1c4e0ea138b6167a555400e405437d73b83bb0af4e9?s=96&d=mm&r=g","caption":"leapfrogbio"},"sameAs":["https:\/\/www.leapfrog.bio"],"url":"https:\/\/www.leapfrog.bio\/fr\/author\/leapfrogbio\/"}]}},"featured_image_src":null,"featured_image_src_square":null,"author_info":{"display_name":"leapfrogbio","author_link":"https:\/\/www.leapfrog.bio\/fr\/author\/leapfrogbio\/"},"_links":{"self":[{"href":"https:\/\/www.leapfrog.bio\/fr\/wp-json\/wp\/v2\/posts\/617","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.leapfrog.bio\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.leapfrog.bio\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.leapfrog.bio\/fr\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.leapfrog.bio\/fr\/wp-json\/wp\/v2\/comments?post=617"}],"version-history":[{"count":7,"href":"https:\/\/www.leapfrog.bio\/fr\/wp-json\/wp\/v2\/posts\/617\/revisions"}],"predecessor-version":[{"id":624,"href":"https:\/\/www.leapfrog.bio\/fr\/wp-json\/wp\/v2\/posts\/617\/revisions\/624"}],"wp:attachment":[{"href":"https:\/\/www.leapfrog.bio\/fr\/wp-json\/wp\/v2\/media?parent=617"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.leapfrog.bio\/fr\/wp-json\/wp\/v2\/categories?post=617"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.leapfrog.bio\/fr\/wp-json\/wp\/v2\/tags?post=617"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}